Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz Oral Solution in Pediatric HIV
NCT00543530Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2001
- Primary completion
- Dec 2002
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of efavirenz in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoint: Safety and Tolerability. Started Mar 2001; status: completed.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00543530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00543530.